Kinsella On Liberty

Kinsella on Liberty Podcast: Episode 465. GROK SHOWNOTES: [0:00–9:16] In this engaging episode of the Kinsella on Liberty podcast, Stephan Kinsella and Sheldon Richman tackle the contentious issue of pharmaceutical price controls under Trump’s executive order, questioning their equivalence to traditional price controls that distort markets. Kinsella, drawing on his extensive critique of intellectual property (Patents and Pharmaceuticals, 2023; Patents, Pharma, Government: The Unholy Alliance, 2024), argues that patents create artificial monopolies, so price controls countering these are not standard interventions but responses to government-granted privileges. Richman highlights FDA-imposed costs, which patents partially offset, though Kinsella counters that these costs are overstated, citing lower drug prices abroad (Drug Reimportation, 2009). They endorse reimportation as a market-based solution, referencing Connor O’Keefe’s analysis (Mises: How Trump Can Lower Drug Prices Without Price Controls, 2025), bu